Novel colloidal carriers for psoriasis: Current issues, mechanistic insight and novel delivery approaches

Journal of Controlled Release

Volumn 170, Issue 3, 2013, Pages 380-395

  Pradhan, Madhulika ^a   Singh, Deependra ^a   Singh, Manju Rawat ^a  

^a PT RAVISHANKAR SHUKLA UNIVERSITY   (India)

Author keywords

Antipsoriatic drugs; Colloidal carriers; Cytokines; Nanocolloidal systems; Psoriasis

Indexed keywords

DERMATOLOGY; DRUG INTERACTIONS; DRUG PRODUCTS;

ANTIPSORIATIC DRUGS; COLLOIDAL CARRIERS; CYTOKINES; NANOCOLLOIDAL SYSTEMS; PSORIASIS;

SKIN;

ADALIMUMAB; AMCINONIDE; BETAMETHASONE; BETAMETHASONE VALERATE; CALCIPOTRIOL; CALCITRIOL; CLOBETASOL; COD LIVER OIL; DITHRANOL; DRUG CARRIER; EFALIZUMAB; ETANERCEPT; ETRETIN; FLUOCINOLONE; GLYCOLIC ACID; HYDROCORTISONE VALERATE; INFLIXIMAB; MOMETASONE FUROATE; OMEGA 3 FATTY ACID; PIMECROLIMUS; PREDNICARBATE; PROPIONIC ACID; SALICYLIC ACID; TACROLIMUS; TAR; TAZAROTENE; TRIAMCINOLONE ACETONIDE; ULOBETASOL PROPIONATE; UNINDEXED DRUG; UREA;

ACNE; ALOPECIA; ANOREXIA; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; APPLICATION SITE PRURITUS; ARTHRALGIA; BURN; BURNING SENSATION; CELL INTERACTION; CHEILITIS; COMPETITIVE INHIBITION; COUGHING; DISEASE EXACERBATION; DIZZINESS; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRY SKIN; DYSPNEA; EFFECTOR CELL; EMULSION; EPISTAXIS; ERYTHEMA; FATIGUE; FLU LIKE SYNDROME; FOLLICULITIS; HAIR LOSS; HEART FAILURE; HUMAN; HYPERCALCEMIA; HYPERTRICHOSIS; HYPERVITAMINOSIS; HYPOPIGMENTATION; INFECTION; INFLAMMATION; LEUKOCYTOSIS; LIPOSOMAL DELIVERY; LIVER FAILURE; LOADING DRUG DOSE; LONG TERM CARE; LYMPHOCYTOSIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MICELLE; NONHUMAN; PAIN; PATHOGENESIS; PERIORAL DERMATITIS; PHOTOTHERAPY; POLYURIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PSORIASIS; PURPURA; RETINOL INTOXICATION; REVIEW; SECONDARY INFECTION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ALLERGY; SKIN ATROPHY; SKIN DEFECT; SKIN DISCOLORATION; SKIN FRAGILITY; SKIN INFECTION; SKIN IRRITATION; SKIN PRURITUS; SORE THROAT; SPONTANEOUS MUTATION; STRIA; SUSTAINED DRUG RELEASE; SWEATING; SWELLING; T LYMPHOCYTE ACTIVATION; TELANGIECTASIA; THIRST; TOPICAL TREATMENT; XENOTRANSPLANTATION; XEROSIS;

ANTIPSORIATIC DRUGS; COLLOIDAL CARRIERS; CYTOKINES; NANOCOLLOIDAL SYSTEMS; PSORIASIS;

ANIMALS; COLLOIDS; DRUG CARRIERS; HUMANS; LIPIDS; POLYMERS; PSORIASIS;

EID: 84885087829     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.05.020     Document Type: Review

References (163)

1. T. Mabuchi, T.W. Chang, S. Quinter, S.T. Hwang, Chemokine receptors in the pathogenesis and therapy of psoriasis, J. Dermatol. Sci. 65 (2012) 4-11.
2. Tsuruta, NF-B links keratinocytes and lymphocytes in the pathogenesis of psoriasis, Recent Patents Inflamm. Allergy Drug Discov. 3 (2009) 40-48.
3. J.G. Krueger, A. Bowcock, Psoriasis pathophysiology: current concepts of patho-genesis, Ann. Rheum. Dis. 64 (2005) 30-36.
4. E.S. Galimova, V.L. Akhmetova, E.K. Khusnutdinova, Molecular genetic basis of susceptibility to psoriasis, Russ. J. Genet. 44 (2008) 513-522. (Pubitemid 351733530)
5. E. Campalani, J.N.W.N. Barker, The clinical genetics of psoriasis, Curr. Genom. 6 (2005) 51-60. (Pubitemid 40403367)
6. K. Reich, K. Kruger, R. Mossner, M. Augustin, Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis, Br. J. Dermatol. 160 (2009) 1040-1047.
7. F.O. Nestle, C. Conrad, Mechanisms of psoriasis, Drug Discov. Today Dis. Mech. 1 (2004) 315-319. (Pubitemid 41128956)
8. S.E. Gillard, A.Y. Finlay, Current management of psoriasis in the United Kingdom: patterns of prescribing and resource use in primary care, Int. J. Clin. Pract. 59 (2005) 1260-1267. (Pubitemid 43904493)
9. L.C. Montero, I. Belinchon, Connective tissue diseases and psoriasis, Actas Dermosifiliogr. 102 (2011) 487-497.
10. J.Y. Fang, C.L. Fang, C.H. Liu, Y.H. Su, Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC), Eur. J. Pharm. Biopharm. 70 (2008) 633-640.
11. B.J. Nickoloff, F.O. Nestle, Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities, J. Clin. Invest. 113 (2004) 1664-1675. (Pubitemid 39071656)
12. M. El-Darouti, R.B. Hay, Psoriasis: highlights on pathogenesis, adjuvant therapy and treatment of resistant and problematic cases (part I), J. Egypt. Women. Dermatol. Soc. 7 (2010) 64-67.
13. A.T. Pietrzak, A. Zalewska, G. Chodorowska, D. Krasowska, A. Michalak-Stoma, P. Nockowski, P. Osemlak, T. Paszkowski, J.M. Roliński, Cytokines and anticytokines in psoriasis, Clin. Chim. Acta 394 (2008) 7-21.
14. C.A. Dinarello, The IL-1 family and inflammatory diseases, Clin. Exp. Rheumatol. 20 (2002) S1-S13. (Pubitemid 35174747)
15. D. Kemmett, J.A. Symons, G.B. Colver, G.W. Duff, Serum-soluble interleukin 2 receptor in psoriasis. Failure to reflect clinical improvement, Acta Derm. Venereol. 70 (1990) 264-267. (Pubitemid 20172438)
16. K. Ghoreschi, P. Thomas, S. Breit, Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease, Nat. Med. 9 (2003) 40-46. (Pubitemid 36098258)
17. K. Asadullah, W. Sterry, U. Trefzer, Cytokines: interleukin and interferon therapy in dermatology, Clin. Exp. Dermatol. 27 (2002) 578-584. (Pubitemid 35463874)
18. T. Hirano, S. Akira, T. Taga, T. Kishimoto, Biological and clinical aspects of inter-leukin 6, Immunol. Today 11 (1990) 443-449.
19. H. Spitz, IL-7, In: J.J. Oppenheim, et al., (Eds.), Cytokine Reference, Academic Press, T.1, San Diego, 2000, pp. 137-153.
20. H. Iizasa, K. Matsushima, IL-8, In: J.J. Oppenheim, et al., (Eds.), Cytokine Reference, Academic Press, T.1, San Diego, 2000, pp. 1061-1067.
21. K. Asadullah, W. Sterry, K. Stephanek, IL-10 is a key cytokine in psoriasis, J. Clin. Invest. 101 (1998) 783-794.
22. Godic, New approaches to psoriasis treatment: a review, Acta Dermatovenerol. 3 (2004) 50-57.
23. M. Berard, K. Brandt, S. Bulfone-Paus, D.F. Tough, IL-15 promotes the survival of naive and memory phenotype CD8+ T cells, J. Immunol. 170 (2003) 5018-5026. (Pubitemid 36554732)
24. J.T. Elder, IL-15 and psoriasis: another genetic link to Th17, J. Invest. Dermatol. 127 (2007) 2495-2497. (Pubitemid 47585052)
25. J. Witowski, K. Ksia̧żek, A. Jörres, Interleukin-17: a mediator of inflammatory responses, Cell. Mol. Life Sci. 61 (2004) 567-579. (Pubitemid 38372911)
26. H. Muhl, J. Pfeilschifter, Interleukin-18 bioactivity: a novel target for immuno-pharmacological anti-inflammatory intervention, Eur. J. Pharmacol. 500 (2004) 63-71. (Pubitemid 39303997)
27. G. Gallagher, J. Eskdale, W. Jordan, Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses, Int. Immunopharmacol. 4 (2004) 615-626. (Pubitemid 38553883)
28. Y.C. Wang, H.H. Li, P.C. Chen, J.H. Hsue, J.J. Yang, M.S. Chang, IL-20: promoter analysis and characterization of biological function, Eur. Cytokine Netw. 14 (2003) 174.
29. S. Aggarwal, N. Ghilardi, M.H. Xie, F.J. de Sauvage, A.L. Gurney, Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17, J. Biol. Chem. 278 (2003) 1910-1914. (Pubitemid 36801431)
30. O.P. Katare, K. Raza, B. Singh, S. Dogra, Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors, Indian J. Dermatol. Venereol. Leprol. 76 (2010) 612-621.
31. M.P. Schon, Animal models of psoriasis: a critical appraisal, Exp. Dermatol. 17 (2008) 703-712. (Pubitemid 352044366)
32. J. Jean, R. Pouliot, In vivo and in vitro models of psoriasis, In: Daniel Eberli (Ed.), Tissue Engineering, 2010, pp. 359-382.
33. H. Mizutani, K. Yamanaka, H. Konishi, T. Murakami, Animal models of psoriasis and pustular psoriasis, Arch. Dermatol. Res. 295 (2003) S67-S68.
34. J.E. Fraki, R.A. Briggaman, G.S. Lazarus, Transplantation of psoriatic skin onto nude mice, J. Invest. Dermatol. 80 (1983) 31s-35s. (Pubitemid 13063556)
35. B.J. Nickoloff, S.L. Kunkel, M. Burdick, R.M. Strieter, Severe combined immunodeficiency mouse and human psoriatic skin chimeras: validation of a new animal model, Am. J. Pathol. 146 (1995) 580-588.
36. O. Boyman, H.P. Hefti, C. Conrad, B.J. Nickoloff, M. Suter, F.O. Nestle, Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha, J. Exp. Med. 199 (2004) 731-736. (Pubitemid 38316440)
37. M. Carretero, S. Guerrero-Aspizua, M. Del Río, Bioengineered skin humanized model of psoriasis, Methods Mol. Biol. 961 (2013) 305-323.
38. S. Guerrero-Aspizua, M. Garcia, R. Murillas, L. Retamosa, N. Illera, B. Duarte, A. Holguín, S. Puig, M.I. Hernández, A. Meana, J.L. Jorcano, F. Larcher, M. Carretero, M. Del Rio, Development of a bioengineered skin-humanized mouse model for psoriasis: dissecting epidermal-lymphocyte interacting pathways, Am. J. Pathol. 177 (2010) 3112-3124.
39. T.M. Zollner, H. Renz, F.H. Igney, K. Asadullah, Animal models of T-cell mediated skin diseases, Bioessays 26 (2004) 693-696. (Pubitemid 38758347)
40. J.C. Cather, W. Abramovits, A. Menter, Cyclosporine and tacrolimus in dermatology, Dermatol. Clin. 19 (2001) 119-137. (Pubitemid 32038050)
41. M. Grassberger Stuetz, J.G. Meingassner, Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity, Semin. Cutan. Med. Surg. 20 (2001) 233-241. (Pubitemid 33139090)
42. C.O. Mendonc, A.D. Burden, Current concepts in psoriasis and its treatment, Pharmacol. Therapeut. 99 (2003) 133-147. (Pubitemid 36897746)
43. J.H.J. Roelofzen, K.K.H. Aben, U.T.H. Oldenhof, P.J. Coenraads, H.A. Alkemade, P.C.M. Van de Kerkhof, P.G.M. Van der Valk, L.A.L.M. Kiemeney, No increased risk of cancer after coal tar treatment in patients with psoriasis and eczema, J. Invest. Dermatol. 130 (2010) 953-961.
44. K. Kragballe, Treatment of psoriasis with calcipotriol and other vitamin D analogues, J. Am. Acad. Dermatol. 27 (1992) 1001-1008.
45. D. Federman, C. Fraelish, Topical psoriasis therapy, Am. Fam. Physician 59 (1999) 957-962. (Pubitemid 29108614)
46. J.W. Fluhr, C. Cavallotti, E. Berardesca, Emollients, moisturizers, and keratolytic agents in psoriasis, Clin. Dermatol. 26 (2008) 380-386.
47. M.M. McCusker, J.M. Grant-Kels, Healing fats of the skin: the structural and immunologic roles of ω3 and ω-6 acids, Clin. Dermatol. 28 (2010) 440-451.
48. B.S. Suvarna, Secrets of omega-3 oil, Kathmandu Univ. Med. J. 6 (2008) 406-411.
49. B. Erardesca, P. Vignoli, D. Istante, R. Ona, Effects of glycolic acid on psoriasis, Clin. Exp. Dermatol. 23 (1998) 190-191.
50. E. Maccaroni, G.B. Giovenzana, G. Palmisano, D. Botta, P. Volante, N. Masciocchi, Structures from powders: diflorasonediacetate, Steroids 74 (2009) 102-111.
51. S. Mohandas, R. Rai, C.R. Srinivas, Halobetasol versus clobetasol: a study of potency, Indian J. Dermatol. Venereol. Leprol. 75 (2009) 186-187.
52. C. Fenton, G.L. Plosker, Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris, Am. J. Clin. Dermatol. 5 (2004) 463-478. (Pubitemid 40178772)
53. P.M. Laws, H.S. Young, Topical treatment of psoriasis, Expert. Opin. Pharmacother. 11 (2010) 1999-2009.
54. C. Crim, L.N. Pierre, P.T. Daley-Yates, A review of the pharmacology and pharma-cokinetics of inhaled fluticasone propionate and mometasone furoate, Clin. Ther. 23 (2001) 1339-1354. (Pubitemid 32912787)
55. M. Pauporte, H. Maibach, N. Lowe, M. Pugliese, D.J. Friedman, H. Mendelsohn, I. Cargill, R. Ramirez, Fluocinolone acetonide topical oil for scalp psoriasis, J. Dermatol. Treat. 15 (2004) 360-364. (Pubitemid 39657846)
56. J. Fowler, M.D. Faad, L. Fowler, Physician and patient assessment of triamcino-lone acetonide spray for steroid responsive dermatoses, J. Clin. Aesthet. Dermatol. 3 (2010) 27-31.
57. L. Naldi, N. Yawalkar, K. Andrzej, O. Jean-Paul, M. Paolo, R. Stefano, M. Giuseppe, Efficacy and Safety of the betamethasone valerate 0.1% plaster in mild-to-moderate chronic plaque psoriasis: a randomized, parallel-group, active-controlled, phase III study, Am. J. Clin. Dermatol. 12 (2011) 191-201.
58. J.D. Rosso, S.F. Friedlander, Corticosteroids: options in the era of steroid-sparing therapy, J. Am. Acad. Dermatol. 53 (2005) S50-S58. (Pubitemid 40828181)
59. A.K. Gupta, M. Chow, Prednicarbate (Dermatop®): profile of a corticosteroid, J. Cutan. Med. Surg. 8 (2004) 244-247.
60. G.D. Weinstein, J.G. Krueger, N.J. Lowe, M. Duvic, D.J. Friedman, B.V. Jegasothy, J.L. Jorizzo, E. Shmunes, E.H. Tschen, D.A. Lew-Kaya, J.C. Lue, J. Sefton, J.R. Gibson, R.A. Chandraratna, Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect, J. Am. Acad. Dermatol. 37 (1997) 85-92. (Pubitemid 27287698)
61. M. Rozenbli, M. Lebwohl, P.I. Spuls, Retrospective study of the efficacy of narrowband UVB and acitretin, J. Dermatol. Treat. 14 (2003) 17-20. (Pubitemid 37474602)
62. J.R. Sullivan, V.A. Preda, Treatments for severe psoriasis, Aust. Prescr. 32 (2009) 14-18.
63. J.G. Kruger, The immunologic basis for the treatment of psoriasis with new biologic agents, J. Am. Acad. Dermatol. 46 (2002) 1-23.
64. K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E. Griffiths, A.M. Nakanishi, R. Zitnik, P.C.V. Kerkhof, L. Melvin, A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction, Br. J. Dermatol. 152 (2005) 1304-1312. (Pubitemid 40933433)
65. R. Saini, William D. Tutrone, Jeffrey M. Weinberg, Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus, Curr. Pharm. Des. 11 (2005) 273-280.
66. L. Winterfield, A. Menter, Infliximab, Dermatol. Ther. 17 (2004) 409-426. (Pubitemid 39390595)
67. N.J. Korman, D.K. Moul, Alefacept for the treatment of psoriasis: a review of the current literature and practical suggestions for everyday clinical use, Semin. Cutan. Med. Surg. 24 (2005) 10-18. (Pubitemid 40410094)
68. M. Uslu, Adalimumab, Anti-inflamm. Anti-allergy Agents Med. Chem. 6 (2007) 217-227.
69. A. Menter, S.K. Tyring, K. Gordon, A.B. Kimball, C.L. Leonardi, R.G. Langley, B.E. Strober, M. Kaul, Y. Gu, M. Okun, K. Papp, Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial, J. Am. Acad. Dermatol. 58 (2008) 106-115. (Pubitemid 350298146)
70. J.J. Berth, The use of ciclosporin in psoriasis, J. Dermatol. Treat. 16 (2005) 258-277.
71. M. Kalariya, A.N. Misra, Methotrexate-loaded solid lipid nanoparticles for topical treatment of psoriasis: formulation and clinical implications, AAPS Pharm. Sci. Technol. 4 (2004) 225-241.
72. M. Lebwohl, S.R. Feldman, R. Walther, P. Morgan, S.W. Gutkin, Clinical management of psoriasis: principles and practice, Cutis 67 (2001) 1-15.
73. G. Wozel, Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas, Clinics Dermatol. 26 (2008) 448-459.
74. M.R. Singh, K. Pradhan, D. Singh, Lipid matrix systems with emphasis on lipid microspheres: potent carriers for transcutaneous delivery of bioactives, Curr. Drug Deliv. 9 (2012) 243-254.
75. J. Sharma, S. Kalra, A. Sharma, S. Ran, Colloidal drug carriers, Internet J. Fam. Pract. 9 (2010).
76. V.P. Torchilin, Structure and design of polymeric surfactant-based drug delivery systems, J. Control. Release 73 (2001) 137-172. (Pubitemid 32544594)
77. S. Talegaonkar, A. Azeem, F.J. Ahmad, R.K. Khar, S.A. Pathan, Z.I. Khan, Microemulsions: a novel approach to enhanced drug delivery, Recent Pat. Drug Deliv. Formul. 2 (2008) 238-257.
78. E. Touitou, H.E. Junginger, N.D. Weiner, T. Nagai, M. Mezei, Liposomes as carriers for topical and transdermal delivery, J. Pharm. Sci. 83 (1994) 1189-1203. (Pubitemid 24282318)
79. C. Lherm, R.H. Müller, F. Puisieux, P. Couvreur, Alkylcyanoacrylate drug carriers II: cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length, Int. J. Pharm. 84 (1992) 13-22.
80. R. Cortesi, E. Esposito, G. Luca, C. Nastruzzi, Production of lipospheres as carriers for bioactive compounds, Biomaterials 23 (2002) 2283-2294. (Pubitemid 34234829)
81. R.H. Muller, E.B. Souto, Cosmetic features and applications of lipid nanoparticles (SLN, NLC), Int. J. Cosmet. Sci. 30 (2008) 157-165. (Pubitemid 351623837)
82. J. Pardeike, A. Hommoss, R.H. Muller, Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products, Int. J. Pharm. 366 (2009) 170-184.
83. G.N. Dhembre, R.S. Moon, R.V. Kshirsagar, A review on polymeric micellar nanocarriers, Int. J. Pharm. Bio. Sci. 2 (2011) 109-116.
84. K. Barbara, B. Maria, Dendrmers: properties and applications, Acta Biochim. Pol. 48 (2001) 199-208.
85. P. Goyal, K. Goyal, V. Kumar, A. Singh, O.P. Katare, D.N. Mishra, Liposomal drug delivery systems-clinical applications, Acta Pharma. 55 (2005) 1-25. (Pubitemid 40562616)
86. V.P. Chandu, A. Arunachalam, S. Jeganath, K. Yamini, K. Tharangini, G. Chaitanya, Niosomes: a novel drug delivery system, Int. J. Novel Trends Pharm. Sci 2 (2012) 25-31.
87. S.T. Prajapati, C.G. Patel, C.N. Patel, Transfersomes: a vesicular carrier system for transdermal drug delivery, AJPBR 2 (2011) 507-524.
88. S. Saraf, S. Paliwal, S. Saraf, Sphingosomes a novel appoach to vesicular drug delivery, Int. J. Cur. Sci. Res. 2 (2011) 63-68.
89. A.A. Wahid, N. Ravouru, R.L. Sawant, Ethosomes: a tool for transdermal drug delivery, Curr Trends Biotechnol. Pharm. 5 (2011) 972-981.
90. J.A.S. Suryawanshi, Phytosome: an emerging trend in herbal drug treatment, J. Med. Genet. Genomics 3 (2011) 109-114.
91. M. Rawat, D. Singh, S. Saraf, Swarnlata Saraf, Nanocarriers: promising vehicle for bioactive drugs, Biol. Pharm. Bull. 29 (2006) 1790-1798. (Pubitemid 44338396)
92. G. Cevc, G. Blume, Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force, Biochem. Biophys. Acta 1104 (1992) 226-232.
93. M. Trotta, E. Peira, M.E. Carlotti, M. Gallarate, Deformable liposomes for dermal administration of methotrexate, Int. J. Pharm. 270 (2004) 119-125. (Pubitemid 38077093)
94. R.V. Kombath, S.K. Minumula, A. Sockalingam, S. Subadhra, S. Parre, R.T. Reddy, B. David, Critical issues related to transfersomes-novel vesicular system, Acta Sci. Pol. Technol. Aliment. 11 (2012) 67-82.
95. G. Cevc, G. Blume, A. Schatzlein, Transfersomes-mediated transepidermal delivery improves the regio-1 specificity and biological activity of corticosteroids in vivo, J. Control. Release 45 (1997) 211-226.
96. G. Cevc, G. Blume, Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage, Biochim. Biophys. Acta 1663 (2004) 61-73. (Pubitemid 38625580)
97. N.V.S. Madhav, A. Saini, Niosomes: a novel drug delivery system, IJRPC 1 (2011) 498-511.
98. P. Pawar Sankhyan, Recent trends in niosome as vesicular drug delivery system, J. Appl. Pharm. Sci. 02 (2012) 20-32.
99. M. Manconi, C. Sinico, D. Valenti, G. Loy, A.M. Fadda, Niosomes as carriers for tretinoin. I. Preparation and properties, Int. J. Pharm. 234 (2002) 237-248. (Pubitemid 34142628)
100. O.P. Katare, R. Agarwal, S.P. Vyas, Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol, Int. J. Pharm. 228 (2001) 43-52. (Pubitemid 32905364)
101. P.K. Lakshmi, G.S. Devi, S. Bhaskaran, S. Sacchidanand, Niosomal methotrexate gel in the treatment of localized psoriasis: phase I and phase II studies, Ind. J. Dermatol. Venereol. Leprol. 73 (2007) 157-162.
102. D.D. Verma, S. Verma, G. Blume, A. Fahr, Particle size of liposomes influences dermal delivery of substances into skin, Int. J. Pharm. 258 (2003) 141-151. (Pubitemid 36712878)
103. P. Saarinen-Savolainen, T. Jarvinen, H. Taipale, A. Urtt, Method for evaluating drug release from liposomes in sink conditions, Int. J. Pharm. 159 (1997) 27-33. (Pubitemid 28062807)
104. M. Mezei, V. Gulasekharam, Liposomes - a selective drug delivery system for the topical route of administration: gel dosage form, J. Pharm. Pharmacol. 34 (1982) 473-474. (Pubitemid 12082555)
105. H.A. Benson, Elastic liposomes for topical and transdermal drug delivery, Methods Mol. Biol. 605 (2010) 77-86.
106. V. Dubey, D. Mishra, N.K. Jain, T. Dutta, M. Nahar, D.K. Saraf, Transdermal drug delivery of antipsoriatic agent via ethanolic liposomes, J. Control. Release 123 (2007) 148-154. (Pubitemid 47562141)
107. A.M. Fadda, M. Manconi, C. Sinico, C. Caddeo, A.O. Vila, D. Valentia, Penetration enhancer containing vesicles as carriers for dermal delivery of tretinoin, Int. J. Pharm. 412 (2011) 37-46.
108. G. Li, C. Fan, X. Li, Y. Fan, X. Wang, M. Li, Y. Liu, Preparation and in vitro evaluation of tacrolimus-loaded ethosomes, Sci. World J. 2012 (2012) 1-6.
109. V. Dubey, D. Mishra, M. Jain, N. Kumar, Novel methothrexate-based topical therapies for effective treatment of psoriasis, Clin. Dermatol. 24 (2008) 124-130.
110. H. Bunjes, Structural properties of solid lipid based colloidal drug delivery systems, Curr. Opin. Colloid Interface Sci. 16 (2011) 405-441.
111. A.H. Sathali, P. Ekambaram, K. Priyanka, Solid lipid nanoparticles: a review, Sci. Revs. Chem. Commun. 2 (2012) 80-102.
112. M. Rawat, D. Singh, S. Saraf, S. Saraf, Lipid carriers: a versatile delivery vehicle for proteins and peptides, Yakugaku Zasshi 128 (2008) 269-280. (Pubitemid 351237899)
113. S. Martins, B. Sarmento, D.C. Ferreira, E.B. Souto, Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles, Int. J. Nanomedicine 2 (2007) 595-607.
114. A.K. Shah, A.A. Date, M.D. Joshi, V.B. Patravale, Solid lipid nanoparticles of tretenoin: potential in topical delivery, Int. J. Pharm. 345 (2007) 163-171. (Pubitemid 350087549)
115. K.K. Sawant, Y. Agrawal, K.C. Petkar, Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis, Int. J. Pharm. 401 (2010) 93-102.
116. L.B. Jensen, E. Magnussson, L. Gunnarsson, C. Vermehren, H.M. Nielsen, K. Petersson, Corticosteroid solubility and lipid polarity control release from solid lipid nanoparticles, Int. J. Pharm. 390 (2010) 53-60.
117. R. Abdullah, C.W. How, R. Abbasalipourkabir, Characterization and stability of nanostructured lipid carriers as drug delivery system, Afr. J. Biotechnol. 10 (2011) 1684-1689.
118. Q. Xia, A. Saupe, R.H. Muller, E.B. Souto, Nanostructured lipid carriers as novel carrier for sunscreen formulations, Int. J. Cosmet. Sci. 29 (2007) 473-482. (Pubitemid 350135103)
119. X. Zhang, J. Liu, H. Qiao, H. Liu, J. Ni, W. Zhang, Y. Shi, Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology, Powder Technol. 197 (2010) 120-128.
120. P.V. Pople, K.K. Singh, Development and evaluation of colloidal modified nanolipid carrier: application to topical delivery of tacrolimus, Eur. J. Pharm. Biopharm. 79 (2011) 82-94.
121. S. Gupta, S.P. Moulik, Biocompatible microemulsions and their prospective uses in drug delivery, J. Pharm. Sci. 97 (2008) 22-43.
122. J. Shaji, M.S. Reddy, Microemulsion as drug delivery system, Pharma. times 36 (2004) 17-24.
123. M.J. Alvarez-Figueroa, J. Blanco-Mendez, Transdermal delivery of methotrexate: iontophoretic delivery from hydrogels and passive delivery from microemulsions, Int. J. Pharm. 215 (2001) 57-65. (Pubitemid 32206604)
124. W.B. Liechty, D.R. Kryscio, B.V. Slaughter, N.A. Peppas, Polymers for drug delivery systems, Ann. Rev. Chem. Biomol. Eng. 1 (2010) 149-173.
125. S. Ehrlich, Y. Booher, D.L. Becerra, W.D. Borris, M.L. Figg, A. Blauvelt Turner, Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study, J. Am. Acad. Dermatol. 50 (2004) 533-540.
126. S. Svenson, D.A. Tomalia, Dendrimers in biomedical applications- reflections on the field, Adv. Drug Deliv. Rev. 64 (2012) 102-115.
127. I. Mishra, Dendrimer: a novel drug delivery system, J. Drug Deliv. Therapeut. 1 (2011) 70-74.
128. V. Gajbhiye, V.K. Palanirajan, R. Tekade, N.K. Jain, Dendrimers as therapeutic agents: a systematic review, J. Pharm. Pharmacol. 61 (2009) 989-1003.
129. S. Gupta, R. Tyagi, V.S. Parmar, S.K. Sharma, R. Haag, Polyether based amphi-philes for delivery of active compounds, Polymer 53 (2012) 3053-3078.
130. S. Wołowiec, K. Borowska, A. Rubaj, K. Głowniak, E. Sieniawska, S. Radej, Effect of polyamidoamine dendrimer G3 and G4 on skin permeation of 8-methoxypsoralene-in vivo study, Int. J. Pharm. 426 (2012) 280-283.
131. D. Singh, M.R. Singh, Development of antibiotic and debriding enzyme loaded PLGA microspheres entrapped in PVA-gelatin hydrogel for complete wound management, Artif. Cells Blood Substit. Immobil. Biotechnol. 40 (2012) 345-353.
132. S. Amin, S. Rajabnezhad, K. Kohli, Hydrogels as potential drug delivery systems, Sci. Res. Essays 3 (2009) 1175-1183.
133. C. Gonçalves, P. Pereira, M. Gama, Self-assembled hydrogel nanoparticles for drug delivery applications, Materials 3 (2010) 1420-1460.
134. K. Nawrotek, R. Zarzycki, Z. Modrzejewska, Drug release from hydrogel matrices, Ecol. Chem. Eng. 17 (2010) 117-135.
135. N.A. Peppas, P. Bures, W. Leobandung, H. Ichikawa, Hydrogels in pharmaceutical formulations, Eur. J. Pharm. Biopharm. 50 (2000) 27-46. (Pubitemid 30326687)
136. S. Baboota, M.S. Alam, S. Sharma, J.K. Sahni, A. Kumar, J. Ali, Nanocarrier based hydrogel of betamethasone dipropionate and salicylic acid for treatment of psoriasis, Int. J. Pharma. Invest. 1 (2011) 139-147.
137. D. Singh, M.R. Singh, S. Saraf, V.K. Dixit, S. Saraf, Formulation optimization of met-ronidazole loaded chitosan microspheres for wound management by 3-factor, 3-level Box-Behnken design, Micro and Nanosystems 2 (2010) 70-77.
138. D. Singh, M. Singh, S. Saraf, V.K. Dixit, S. Saraf, Optimization and characterization of gentamicin loaded chitosan microspheres for effective wound healing, Indian J. Pharm. Educ. Res. 44 (2010) 171-182.
139. M. Alagusundaram, M. Sudana, C. Chetty, K. Umashankari, V.B. Attuluri, C. Lavanya, R. Set, Microspheres as a novel drug delivery system - a review, Int. J. Chem. Tech. Res. 1 (2009) 526-534.
140. C. Berkland, M.J. Kipper, B. Narasimhan, K. Kim, D.W. Pack, Microsphere size, precipitation kinetics, and drug distribution control drug release from biodegradable polyanhydride microspheres, J. Controlled Release 94 (2004) 129-141. (Pubitemid 37542383)
141. S. Khan, T. Tiwari, N. Rao, A. Joshi, B.K. Dubey, Microspheres: a review, WJPPS 1 (2012) 125-145.
142. U. Badilli, T. Şen, N. Tarimci, Microparticulate. Based topical delivery system of clobetasol propionate, AAPS Pharm. Sci. Tech. 12 (2011) 949-957.
143. R. Dinarvand, E. Rahmania, E. Farboda, Gelatin microspheres for the controlled release of all-trans-retinoic acid topical formulation and drug delivery evaluation, Iran. J. Pharma. Res. (2003) 47-50.
144. G.P. Carino, J.S. Jacob, E. Mathiowitz, Nanosphere based oral insulin delivery, J. Control. Release 65 (2000) 261-269. (Pubitemid 30122931)
145. K.S. Soppimath, T.M. Aminabhavi, A.R. Kulkarni, W.E. Rudzinski, Biodegradable polymeric nanoparticles as drug delivery devices, J. Control. Release 70 (2001) 1-20. (Pubitemid 32144788)
146. T. Ishihara, T. Kubota, T. Choi, M. Takahashi, E. Ayano, H. Kanazawa, M. Higaki, Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness, Int. J. Pharm. 375 (2009) 148-154.
147. K. Letchford, H. Burt, A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes, Eur. J. Pharm. Biopharm. 65 (2007) 259-269. (Pubitemid 46321600)
148. C.E. Mora-Huertasa, H. Fessi, A. Elaissari, Polymer-based nanocapsules for drug delivery, Int. J. Pharm. 385 (2010) 113-142.
149. P.R. Radhika, T. Sivakumar Sasikanth, Nanocapsules: a new approach in drug delivery, Int. J. Pharm. Sci. Res. 2 (2011) 1426-1429.
150. A.F. Ourique, A.R. Pohlmann, S.S. Gutees, R.C. Beck, Tretinoin-loaded nanocapsules: preparation, physicochemical characterization, and photostability study, Int. J. Pharm. 352 (2008) 1-4.
151. P. Srisuk, P. Thongnopnua, U. Raktanonchai, S. Kanokpanont, Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment, Int. J. Pharm. 427 (2012) 426-434.
152. B.M. Bianca, L.Q. Arturo, M. Begon, D. Charro, A.M. Fadda, J. Blanco-Me'ndez, Microemulsions for topical delivery of 8-methoxsalen, J. Control. Release 69 (2000) 209-218.
153. S.B. Goebela, H.H. Reinhard, J. Wohlrabb Neuberta, Dermal targeting of tacroli-mus using colloidal carrier systems, Int. J. Pharm. 404 (2011) 159-168.
154. C.M. Heard, S. Gillian, L. Singka, N.A. Samah, M.H. Zulfakar, A. Yurdasiper, Enhanced topical delivery and anti-inflammatory activity of methotrexate from an activated nanogel, Eur. J. Pharm. Biopharm. 76 (2010) 275-281.
155. F.Q. Aline, A. Melero, C. Bona da Silva, F.S. Ulrich, A.R. Pohlmann, S.S. Guterres, C.M. Lehr, K.H. Kostka, R.C.R. Beck, Improved photostability and reduced skin permeation of tretinoin: development of a semisolid nanomedicine, Eur. J. Pharm. Biopharm. 79 (2011) 95-101.
156. V. Doktorovova, J. Araujo, M.L. Garcia, E. Rakovsky, E.B. Souto, Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC), Colloids Surf., B. 75 (2010) 538-542.
157. M.C. Fontana, J.F.P. Rezer, K. Coradini, D.B.R. Leal, R.C.R. Beck, Improved efficacy in the treatment of contact dermatitis in rats by a dermatological nanomedicine containing clobetasol propionate, Eur. J. Pharm. Biopharm. 79 (2011) 241-249.
158. Y.K. Lin, Z.R. Huang, R.Z. Zhuo, J.Y. Fang, Combination of calcipotriol and methotrex-ate in nanostrucured lipid carrier for topical delivery, Int. J. Nanomed. 5 (2010) 117-128.
159. D.M. Ridolfi, P.D. Marcato, G.Z. Justo, L. Cordi, D. Machado, N. Durán, Chitosan-solid lipid nanoparticles as carriers for topical delivery of tretinoin, Colloids Surf., B. 93 (2012) 36-40.
160. N.O. Knudsen, S. Rønholt, R.D. Salte, L. Jorgensen, T. Thormann, L.H. Basse, J. Hansen, S. Frokjaer, C. Foged, Calcipotriol delivery into the skin with PEGylated liposomes, Int. J. Pharm. 345 (2007) 163-171.
161. J.M. Fachinetto, A.F. Ourique, G. Lubini, S.B. Tedesco, A.C.F. Silva, R.C.R. Beck, Tretinoin-loaded polymeric nanocapsules: evaluation of the potential to improve the antiproliferative activities on allium cepa root-tip compared to the free drug, Lat. Am. J. Pharm. 27 (2008) 668-673.
162. M.L. Marchiori, G. Lubini, G. Dalla Nora, R.B. Friedrich, M.C. Fontana, A.F. Ourique, M.O. Bastos, L.A. Rigo, C.B. Silva, S.B. Tedesco, R.C.R. Beck, Hydrogel containing dexamethasone-loaded nanocapsules for cutaneous administration: preparation, characterization, and in vitro drug release study, Drug Dev. Ind. Pharm. 36 (2010) 962-971.
163. D. Singh, P. Dubey, M. Pradhan, M.R. Singh, Ceramic nanocarriers: versatile nanosystem for protein and peptide delivery, Expert Opin. Drug Deliv. 10 (2013) 241-259.